- AVITA Medical ( NASDAQ: RCEL ) on Monday said it had submitted a premarket approval application to the U.S. FDA seeking an expansion of the indication of its RECELL system to treat vitiligo.
- Vitiligo is a skin disease that causes discoloration and loss of skin color in patches.
- The approval application was supported by results from RCEL's trial for vitiligo, the company said in a statement .
- RCEL last week submitted another premarket approval supplement application to the FDA for the RECELL system seeking expansion of its indication to include soft tissue repair.
- AVITA ( RCEL ) stock -5.4% to $6.60 in mid-day trade.
For further details see:
AVITA Medical seeks FDA nod to expand indication of its system to treat vitiligo